Dianthus Therapeutics Inc
DNTH
NASDAQ
Biotechnology
$115.96
USD
+6.36 (+5.80%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.19B
Volume 897.2K
Revenue
$1.90M
TTM
-60.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-192.25M
TTM
-67.5%
YoY
Operating Cash Flow
$-155.38M
TTM
-55.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.2 | 0.4 | 0.3 | 0.5 | 0.8 |
YoY Growth | -89.6% | -81.8% | -78.6% | -60.2% | +294.3% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.2 | 0.4 | 0.3 | 0.5 | 0.8 |
Selling, General & Administrative | 8.9 | 8.2 | 9.9 | 12.5 | 13.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 35.1 | 40.7 | 69.8 | 47.0 | 62.2 |
Operating Income | -34.9 | -40.3 | -69.5 | -46.5 | -61.5 |
EBITDA | -34.9 | -40.3 | -69.5 | -46.5 | -61.4 |
Other Income / Expense | -0.1 | -0.1 | -0.2 | -0.6 | -0.3 |
Total Other Income / Expense | 3.3 | 3.5 | 5.1 | 5.7 | 11.3 |
Income Before Income Taxes | -31.6 | -36.8 | -64.4 | -40.8 | -50.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -31.6 | -36.8 | -64.4 | -40.8 | -50.2 |
Consolidated Net Income / Loss | -31.6 | -36.8 | -64.4 | -40.8 | -50.2 |
Net Income Attributable to Common Shareholders | -31.6 | -36.8 | -64.4 | -40.8 | -50.2 |
Basic EPS | -$0.88 | -$0.97 | -$1.43 | -$0.85 | -$0.90 |
Diluted EPS | -$0.88 | -$0.97 | -$1.43 | -$0.85 | -$0.90 |
Basic Shares Outstanding | 35.8M | 37.8M | 45.1M | 48.0M | 56.0M |
Diluted Shares Outstanding | 35.8M | 37.8M | 45.1M | 48.0M | 56.0M |